Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2013-09-02Clinical Trial Update: A Study of Duloxetine in Elderly Generalized Anxiety Disorder [Phase 4]
Phase 4 study evaluating duloxetine in elderly patients with Generalized Anxiety Disorder completed; results were posted in 2013.
-
CLINICAL_TRIALS trial_result · 2013-08-20Clinical Trial Update: Lifestyle Interventions for Generalized Anxiety Disorder [NA]
A clinical trial evaluating lifestyle interventions for Generalized anxiety disorder, including aerobic exercise and stretching, has been te…
-
FDA approval · 2013-07-31FDA Approved: ESCITALOPRAM — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)
FDA approves Jubilant Cadista's supplemental application for escitalopram oxalate (generic escitalopram), expanding availability of a generi…
-
FDA approval · 2013-07-31FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for escitalopram oxalate (generic antidepressant) from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2013-07-26FDA Approved: DOXEPIN — Original Application (Actavis Pharma, Inc.)
The FDA approved Actavis Pharma, Inc.'s generic doxepin as an original ANDA, providing a generic option for this antidepressant.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-06-28FDA Approved: PAROXETINE — Original Application (Padagis US LLC)
FDA approved a paroxetine product from Padagis US LLC under an original application.
-
CLINICAL_TRIALS trial_result · 2013-06-19Clinical Trial Update: RCT of an Acceptance-based Behavior Therapy for GAD [NA]
This document reports the completion of a randomized controlled trial evaluating Acceptance-based Behavior Therapy for Generalized Anxiety D…
-
FDA approval · 2013-06-12FDA Approved: ESCITALOPRAM ORAL SOLUTION — Original Application (Chartwell RX, LLC)
FDA approved a generic escitalopram oral solution from Chartwell RX, LLC under an Original Application (ANDA). It is indicated for major dep…
-
CLINICAL_TRIALS trial_result · 2013-06-11Clinical Trial Update: Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects [Phase 4]
Phase 4 clinical trial update from Massachusetts General Hospital evaluating stress reduction techniques on anxiety and related neuroendocri…
-
FDA approval · 2013-06-10FDA Approved: ESCITALOPRAM — Supplemental Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare Inc.'s supplemental application for escitalopram (generic) under ANDA202389. This approval marks a supplement…
-
FDA approval · 2013-05-31FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for escitalopram oxalate from Rising Pharma Holdings, Inc., approving a generic version under the AN…
-
FDA approval · 2013-05-31FDA Approved: ESCITALOPRAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved the supplemental application for escitalopram oxalate by Aurobindo Pharma Limited, enabling continued generic production and di…
-
FDA approval · 2013-05-21FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for escitalopram oxalate from Macleods Pharmaceuticals Limited, allowing the generic product to be m…
-
FDA approval · 2013-05-20FDA Approved: ESCITALOPRAM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for ESCITALOPRAM (escitalopram oxalate) from Sun Pharmaceutical Industries, Inc., approving this gen…
-
CLINICAL_TRIALS trial_result · 2013-04-19Clinical Trial Update: Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder [Phase 4]
Phase 4 trial evaluating safety and efficacy of pregabalin (Lyrica) in generalized anxiety disorder has completed with results posted in 201…
-
CLINICAL_TRIALS trial_result · 2013-04-02Clinical Trial Update: Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders [Phase 2, Phase 3]
This document reports the results of cognitive-behavioral therapy for anxiety disorders in children with autism spectrum disorders across Ph…
-
FDA approval · 2013-02-28FDA Approved: PREGABALIN — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for pregabalin from Mylan Pharmaceuticals Inc. The approval confirms regulatory status of the generi…
-
CLINICAL_TRIALS trial_result · 2013-02-18Clinical Trial Update: Anxiety in Recovering Opiate Dependence [Phase 4]
Phase 4 trial evaluating anxiety in people recovering from opioid dependence. The study was terminated and results were posted in 2013.
-
CLINICAL_TRIALS trial_result · 2012-12-31Clinical Trial Update: Neural Functioning Underlying Anxiety and Its Treatment (The INSULA Study) [NA]
A completed clinical trial update (INSULA study) from UC San Diego examining neural functioning underlying anxiety and its treatment, focusi…
-
FDA approval · 2012-12-18FDA Approved: PAXIL — Supplemental Application (Apotex Corp)
The FDA approved a supplemental application for Paxil (paroxetine hydrochloride) submitted by Apotex Corp.
-
FDA approval · 2012-12-18FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Effexor XR (venlafaxine hydrochloride) submitted by Viatris Specialty LLC.
-
FDA approval · 2012-12-11FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Vertical Pharmaceuticals, LLC)
The FDA approved a supplemental application for venlafaxine hydrochloride from Vertical Pharmaceuticals, LLC, expanding the drug’s approved …
-
CLINICAL_TRIALS withdrawal · 2012-12-03Clinical Trial Update: 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD) [Phase 3]
Pfizer's Phase 3 open-label safety study of PD-0332334 in elderly patients with Generalized Anxiety Disorder has been withdrawn.
-
FDA approval · 2012-11-29FDA Approved: ALPRAZOLAM — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for alprazolam from Sandoz Inc under an Abbreviated New Drug Application, resulting in an approved a…
-
FDA approval · 2012-11-29FDA Approved: ALPRAZOLAM — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for Alprazolam by Sandoz Inc, a generic benzodiazepine used to treat anxiety disorders such as g…